Related Experiment Video
Updated: Feb 13, 2026

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Manuela Porru1, Luca Pompili1,2, Carla Caruso2
1UOSD SAFU, Regina Elena National Cancer Institute, Rome, Italy.
Abstract:
Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.
Insights
Targeting KRAS, a key cancer-driving oncogene, has been difficult for 30 years. This review covers new strategies for blocking KRAS function and signaling, including our group's research findings.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS is the most frequently mutated oncogene in human cancers.
- Despite extensive efforts over 30 years, developing effective KRAS-targeting drugs has remained a significant challenge.
- KRAS plays a critical role as a driver oncogene in cancer development and progression.
Purpose of the Study:
- To review emerging experimental strategies for inhibiting KRAS function and signaling pathways.
- To discuss the direct targeting of KRAS as a therapeutic approach.
- To present research findings from our group in the field of KRAS drug development.
Main Methods:
- Literature review of current KRAS targeting strategies.
- Analysis of experimental approaches for blocking KRAS activity.
- Presentation of original research data on KRAS targeting.
Main Results:
- Highlighting novel experimental strategies for KRAS inhibition.
- Demonstrating progress in directly targeting KRAS.
- Reporting specific results achieved by our research group in this area.
Conclusions:
- Pharmacological targeting of KRAS remains a critical unmet need in cancer therapy.
- Emerging strategies show promise for overcoming previous challenges in KRAS drug development.
- Continued research, including our group's contributions, is vital for advancing KRAS-targeted cancer treatments.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Emerging Adulthood
Introduction Cardiac Emergencies
Electrical Current
Applications of GIS: Disaster Management and Emergency Response
Current Density

